相似文献
1
Mechanisms to explain the overshoot in bone remodeling markers after denosumab discontinuation: are we there yet?
J Bone Miner Res. 2025 Mar 15;40(3):299-300. doi: 10.1093/jbmr/zjaf007.
2
The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation.
J Bone Miner Res. 2025 Mar 15;40(3):301-306. doi: 10.1093/jbmr/zjae170.
3
Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation.
JCI Insight. 2023 Sep 22;8(18):e167790. doi: 10.1172/jci.insight.167790.
4
Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation.
Front Endocrinol (Lausanne). 2020 May 15;11:250. doi: 10.3389/fendo.2020.00250. eCollection 2020.
5
Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition.
J Bone Miner Res. 2024 May 2;39(4):484-497. doi: 10.1093/jbmr/zjae023.
6
Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation.
Curr Osteoporos Rep. 2022 Dec;20(6):505-515. doi: 10.1007/s11914-022-00756-5. Epub 2022 Oct 6.
7
Early and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of receptor activator of nuclear factor kappa-B ligand inhibition.
J Bone Miner Res. 2025 Mar 15;40(3):413-427. doi: 10.1093/jbmr/zjaf008.
8
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.
Bone. 2017 Dec;105:11-17. doi: 10.1016/j.bone.2017.08.003. Epub 2017 Aug 5.
9
Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.
Osteoporos Int. 2016 May;27(5):1917-21. doi: 10.1007/s00198-015-3458-6. Epub 2015 Dec 22.
10
The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial.
Osteoporos Int. 2024 Feb;35(2):255-263. doi: 10.1007/s00198-023-06932-2. Epub 2023 Oct 6.
本文引用的文献
1
Cellular signatures in human blood track bone mineral density in postmenopausal women.
JCI Insight. 2024 Nov 22;9(22):e178977. doi: 10.1172/jci.insight.178977.
2
The effects of denosumab on osteoclast precursors in postmenopausal women: a possible explanation for the overshoot phenomenon after discontinuation.
J Bone Miner Res. 2025 Mar 15;40(3):301-306. doi: 10.1093/jbmr/zjae170.
3
Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition.
J Bone Miner Res. 2024 May 2;39(4):484-497. doi: 10.1093/jbmr/zjae023.
4
Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation.
JCI Insight. 2023 Sep 22;8(18):e167790. doi: 10.1172/jci.insight.167790.
5
Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption.
Cell. 2021 Apr 1;184(7):1940. doi: 10.1016/j.cell.2021.03.010.
6
Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.
J Bone Miner Res. 2018 Feb;33(2):190-198. doi: 10.1002/jbmr.3337. Epub 2017 Nov 22.
7
Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.
Eur J Endocrinol. 2017 Jun;176(6):677-683. doi: 10.1530/EJE-16-1027. Epub 2017 Mar 10.
8
Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.
J Clin Endocrinol Metab. 2011 Apr;96(4):972-80. doi: 10.1210/jc.2010-1502. Epub 2011 Feb 2.
9
Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
J Bone Miner Res. 2011 Feb;26(2):242-51. doi: 10.1002/jbmr.212.
10
Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
N Engl J Med. 2009 Aug 20;361(8):756-65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11.
Zotero 插件